Journal article icon

Journal article

Effect of nateglinide on the incidence of diabetes and cardiovascular events.

Abstract:

BACKGROUND: The ability of short-acting insulin secretagogues to reduce the risk of diabetes or cardiovascular events in people with impaired glucose tolerance is unknown. METHODS: In a double-blind, randomized clinical trial, we assigned 9306 participants with impaired glucose tolerance and either cardiovascular disease or cardiovascular risk factors to receive nateglinide (up to 60 mg three times daily) or placebo, in a 2-by-2 factorial design with valsartan or placebo, in addition to part...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1056/nejmoa1001122

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
RDM
Sub department:
OCDEM
Role:
Author
Journal:
New England journal of medicine More from this journal
Volume:
362
Issue:
16
Pages:
1463-1476
Publication date:
2010-04-01
DOI:
EISSN:
1533-4406
ISSN:
0028-4793

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP